Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

AI Voice Calls Versus Text and Email Reminders for Questionnaire Response After Shoulder Arthroplasty (VOICE-REACH)

Proactive Conversational Artificial Intelligence Calls Versus Digital Reminders to Collect Patient-Reported Outcomes After Shoulder Arthroplasty: A Randomized Study Within a Multicenter Cohort

After shoulder replacement surgery, surgeons send questionnaires to their patients to learn how they are doing (pain, shoulder function, satisfaction). Many patients do not answer. This study tests the best way to obtain these answers.

The study is nested in a multicenter study of pain after shoulder arthroplasty conducted in four French centers (host study RetroPAinRSACAll, supported by Ramsay Santé). The clinical results of the host study are not the subject of this registration: this study evaluates only the method used to collect the information.

All patients first receive an email invitation (when an email address is available) and, the next day, a text message (SMS) with a personal link to the questionnaire and a phone number to answer at any time by talking with an automated voice assistant. Patients who have not answered two days after the first contact are randomly assigned to one of two follow-up strategies: (1) further digital reminders (SMS on day 3 and day 5, email on day 7), or (2) up to three phone calls from a conversational artificial intelligence (AI) voice agent on days 3, 5 and 7, which asks the same questions orally. In both groups, patients can answer at any time online or by calling the voice assistant, and contacts stop as soon as the questionnaire is completed or the patient refuses.

The main outcome is the proportion of patients who complete the questionnaire within 14 days of the first contact.

Aperçu de l'étude

Description détaillée

Design. VOICE-REACH is a pragmatic, multicenter, individually randomized, two-arm, open-label superiority study within a trial (SWAT). It is embedded in the host study RetroPAinRSACAll (persistent pain after shoulder arthroplasty, four French shoulder surgery centers, favorable opinion of the Ramsay Santé scientific committee, reference COS-RGDS-2026-07-008). All patients of the host cohort are contacted through the DeepCall platform on behalf of their surgeon to complete the host study questionnaire (operation details, warning signs, pain screening and characterization, rehabilitation and function including the Subjective Shoulder Value, opinion on the operation and on the contact). The comparison concerns the follow-up strategy only: the questionnaire is the same in both arms and the same on the web and by voice.

Common phase (all participants). Day 0: email invitation with a personal questionnaire link, sent when an email address is available. Day 1: SMS with the same link, the phone number of the AI voice agent (available 24 hours a day for inbound calls) and an opt-out option (reply NO). Patients are contacted in successive waves of up to 450 patients, one day apart, to respect operator sending limits; all study days are counted from each participant's own day 0.

Randomization. On day 2, participants who have not completed the questionnaire and have not refused are randomized 1:1 by the platform, using a computer-generated permuted block sequence (blocks of 4) stratified by center. Participants who completed the questionnaire before day 2 are not randomized and are described separately.

Arm A, digital reminders: SMS reminders on day 3 and day 5 and an email reminder on day 7 (when an email address is available).

Arm B, proactive AI calls: outbound calls from the AI voice agent on day 3, day 5 and day 7 (up to three attempts). The agent calls on behalf of the surgeon's team and asks the questionnaire orally; answers are extracted into the same structured fields as the web form.

In both arms, the web link and the inbound voice line remain available throughout, and all scheduled contacts stop as soon as the questionnaire is completed, the patient refuses, or the patient is identified as deceased. Warning signs reported by patients are flagged to the surgical team for review; the AI agent does not give medical advice.

Analysis. The primary analysis is intention to treat among all randomized participants: proportion with a completed questionnaire by day 14, risk difference (Arm B minus Arm A) with 95% confidence interval, adjusted for center and email availability. Participants without a completed questionnaire by day 14 are counted as non-completers; no answer is imputed. Secondary analyses describe the yield of the common phase, time to completion, completion channel, partial responses, refusals, number of contacts and cost per completed questionnaire, acceptability of the contact mode among responders, representativeness of responders, and the accuracy of voice-captured answers.

Registration timing. The common pre-randomization outreach started on 9 November 2026. This record was created on 10 November 2026, before the first randomization (day 2 of the first wave, 11 November 2026).

Type d'étude

Interventionnel

Inscription (Estimé)

846

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Caen, France, 14000
        • Recrutement
        • Hôpital Privé Saint-Martin
        • Chercheur principal:
          • Franck Dordain, MD
      • Lyon, France, 69008
        • Recrutement
        • Centre Orthopédique Santy, Hôpital Privé Jean Mermoz
        • Chercheur principal:
          • Arnaud Godenèche, MD
      • Paris, France, 75019
        • Recrutement
        • Clinique des Maussins-Nollet
        • Chercheur principal:
          • Geoffroy Nourissat, MD, PhD
      • Strasbourg, France, 67000
        • Recrutement
        • Clinique de l'Orangerie
        • Chercheur principal:
          • Maxime Antoni, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age 18 years or older
  • Shoulder arthroplasty (reverse, anatomic, humeral head replacement or revision arthroplasty) performed at one of the four participating centers and listed in the host study cohort
  • At least one telephone number available (an email address is not required)

Additional criteria for randomization (day 2):

* Questionnaire not completed and no refusal at the day-2 cutoff

Exclusion Criteria:

  • Death identified before the first contact (cross-check with the French national death registry, INSEE)
  • Duplicate record
  • Refusal of contact
  • Questionnaire already completed before day 2 (excluded from randomization only, described separately)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Recherche sur les services de santé
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Digital Reminders

Common phase: email invitation on day 0 (if an email address is available) and SMS invitation on day 1 with the questionnaire link and the AI voice agent phone number. After randomization on day 2: SMS reminder on day 3, SMS reminder on day 5 and email reminder on day 7 (if an email address is available). Participants can answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal.

Standardized reminder messages sent by the DeepCall platform on behalf of the surgeon: SMS on day 3 and day 5 and email on day 7 (if an email address is available), each with the personal questionnaire link, the AI voice agent phone number and an opt-out option.

Expérimental: Proactive AI Voice Calls

Same common phase (email on day 0 if available, SMS on day 1). After randomization on day 2: up to three outbound calls from the conversational AI voice agent on day 3, day 5 and day 7, during which the same questionnaire is asked orally. Participants can also answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal.

Outbound telephone calls placed by a conversational AI voice agent (DeepCall platform) on day 3, day 5 and day 7, up to three attempts. The agent calls on behalf of the surgeon's team, conducts the same questionnaire orally and records the answers in the same structured fields as the web form.

Autres noms:
  • DeepCall

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Questionnaire Completion by Day 14 Among Randomized Participants
Délai: From day 0 (first contact) to day 14

Proportion of randomized participants with a completed questionnaire within 14 days of their first contact (day 0), whatever the channel used (web link, inbound call or outbound AI call). A questionnaire is complete when it was submitted on the web or when all required items were answered during a voice interview. Participants without a completed questionnaire at the day-14 cutoff are counted as non-completers. Compared between arms (proactive AI voice calls minus digital reminders).

From day 0 (first contact) to day 14

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Questionnaire Completion by Day 7 Among Randomized Participants
Délai: From day 0 to day 7

Proportion of randomized participants with a completed questionnaire by day 7, whatever the channel used.

From day 0 to day 7
Time to Questionnaire Completion
Délai: From day 2 to day 14

Time in hours from randomization (day 2) to questionnaire completion among randomized participants; participants without a completed questionnaire are censored at day 14.

From day 2 to day 14
Questionnaire Completion Before Randomization
Délai: From day 0 to day 2

Proportion of all enrolled participants who completed the questionnaire after the common email (day 0) and SMS (day 1) invitations, before the day-2 randomization.

From day 0 to day 2
Questionnaire Completion by Day 14 in All Enrolled Participants
Délai: From day 0 to day 14

Proportion of all enrolled participants, randomized or not, with a completed questionnaire by day 14.

From day 0 to day 14
Partial Questionnaire Response
Délai: From day 0 to day 14

Proportion of randomized participants who answered at least one question without completing the questionnaire by day 14.

From day 0 to day 14
Completion Channel
Délai: From day 0 to day 14

Distribution of completed questionnaires by channel (web link, inbound call to the voice agent, outbound AI call), by arm.

From day 0 to day 14
Refusal of Contact
Délai: From day 2 to day 14

Proportion of randomized participants who explicitly refused further contact (SMS reply, email refusal link or refusal during a call).

From day 2 to day 14
Number of Contacts per Completed Questionnaire
Délai: From day 0 to day 14

Number of emails, SMS and outbound calls sent or attempted, divided by the number of completed questionnaires, by arm.

From day 0 to day 14
Direct Cost per Completed Questionnaire
Délai: From day 0 to day 14

Direct costs of messaging, telephony and AI processing (euros) divided by the number of completed questionnaires, by arm, and incremental cost per additional completed questionnaire.

From day 0 to day 14
Satisfaction With the Mode of Contact
Délai: From day 0 to day 14

Among participants who completed the questionnaire: satisfaction with the way they were contacted, rated on a 5-level scale from very satisfied to very dissatisfied.

From day 0 to day 14
Perceived Number of Contacts
Délai: From day 0 to day 14

Among participants who completed the questionnaire: perceived number of contacts (too many, appropriate, too few).

From day 0 to day 14
Preferred Contact Mode for Future Follow-up
Délai: From day 0 to day 14

Among participants who completed the questionnaire: preferred mode of contact for future follow-up questionnaires (categorical).

From day 0 to day 14
Characteristics of Responders Versus Non-Responders
Délai: Day 14

Age, center, type of arthroplasty and time since surgery (when available in the host cohort) compared between participants who completed the questionnaire and those who did not, by arm (standardized differences).

Day 14
Agreement Between Voice-Captured Answers and Human Review
Délai: From day 0 to day 14

In a random sample of completed voice interviews, agreement between the answers extracted by the AI agent and those coded by a reviewer listening to the recording, blinded to the extracted values (percentage agreement, kappa or intraclass correlation coefficient).

From day 0 to day 14

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Delivery of Email and SMS Invitations
Délai: From day 0 to day 7

Proportion of emails and SMS delivered, bounced or filtered by the operator, as reported by the sending providers.

From day 0 to day 7
Outbound Call Outcomes
Délai: From day 3 to day 7

Distribution of outbound AI call outcomes (answered, voicemail, no answer, filtered, failed) and call duration in the proactive AI voice calls arm.

From day 3 to day 7

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Jules Descamps, MD, MSc, Hopital Lariboisière
  • Chaise d'étude: Geoffroy Nourissat, MD, PhD, Clinique des Maussins-Nollet, Ramsay Santé

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 novembre 2026

Achèvement primaire (Estimé)

24 novembre 2026

Achèvement de l'étude (Estimé)

24 novembre 2026

Dates d'inscription aux études

Première soumission

10 novembre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Identifiable data, call recordings and transcripts will not be shared. Aggregated results will be published.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner